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Abstract. Since 1991, a nationwide histopathology and cytopathology network and archive is in operation in The Netherlands
under the name PALGA, encompassing all sixty-four pathology laboratories in The Netherlands. The overall system comprises
decentralized systems at the participating laboratories, a central databank, and a dedicated communication and information ex-
change tool. Excerpts of all histopathology and cytopathology reports are generated automatically at the participating laborato-
ries and transferred to the central databank. Both the decentralized systems and the central system perform checks on the quality
and completeness of excerpts. Currently, about 42 million records on almost 10 million patients are stored in the central data-
bank. Each excerpt contains patient identifiers, including demographic data and the so-called PALGA diagnosis. The latter is
structured along five classification axes: topography, morphology, function, procedure, and diseases. All data transfer and com-
munication occurs electronically with encryption of patient and laboratory identifiers. All excerpts are continuously available to
all participating pathology laboratories, thus contributing to the quality of daily patient care. In addition, external parties may
obtain permission to use data from the PALGA system, either on an ongoing basis or on the basis of a specific permission.
Annually, 40 to 60 applications for permission to use PALGA data are submitted. Among external users are the Dutch cancer
registry, population-based screening programs for cancer of the uterine cervix and breast cancer in The Netherlands, and indi-
vidual investigators addressing a range of research questions. Many scientific papers and theses incorporating PALGA data have
been published already. In conclusion, the PALGA system is a unique system that requires a minimal effort on the part of the
participating laboratories, while providing them a powerful tool in their daily practices.
Keywords: Central pathology archive, histopathology, cytopathology, information exchange, PALGA, cancer registry, cancer
screening, biobanking
1. Introduction
Pathology laboratories associated with hospitals and
clinics generate a host of data that are useful for
decision making at the level of the individual pa-
tient, but also in a broader context. In order to fa-
cilitate the optimal use of histopathology and cy-
topathology data, a unique, nationwide network and
archive has been set up in the Netherlands under the
*Corresponding author: G.A. Meijer, VU University Medical
Center, Room 3E46, PO Box 7057, 1007 MB Amsterdam, The
Netherlands. E-mail: ga.meijer@vumc.nl.
name PALGA (‘Pathologisch Anatomisch Landelijk
Geautomatiseerd Archief’; Pathological Anatomy Na-
tional Automated Archive; www.palga.nl). PALGA
was founded by a number of pathology laboratories
in 1971. The aims of PALGA were, and still are, to
promote communication and information exchange be-
tween participating histopathology and cytopathology
laboratories and to provide potentially useful data to
others in the health care field in the interest of patient
care and research. This paper provides an outline of the
PALGA system and its main usage.
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Fig. 1. Organizational scheme of the PALGA system with decentralized input by local laboratories, the central databank and information exchange
technology providing authorized users access to the data. The CIPA retrieval box is the interface that allows queries based on diagnosis codes,
demographic factors and conclusion texts of pathology reports.
2. Organization and operations of PALGA
Between 1971 and 1991, an increasing number of
laboratories joined PALGA such that virtually com-
plete national coverage was achieved [1]. Currently,
the globally unique PALGA databank contains about
42 million excerpts on nearly 10 million patients. It is
growing at a rate of over two million excerpts per year
by the online addition of new excerpts on a daily basis.
The PALGA network and registry comprise three
components: decentralized information systems at all
64 participating laboratories, a central databank, and
a dedicated communication and information exchange
infrastructure (Fig. 1). The complete system is su-
pervised and managed by the PALGA Foundation,
supported by a small administrative office, based in
Utrecht, and several external service providers. Apart
from its executive committee, the organisation includes
several special committees dealing with privacy issues,
scientific exploitation of the databank, and other issues.
2.1. Decentralized information system
From the inception of PALGA, it has been the pol-
icy to tap the relevant information at the site of ori-
gin (i.e. the participating laboratories) on an ongoing
basis and avoid the need for additional efforts by the
participating laboratories. This aim has been achieved
by using decentralized information systems running
on the local computer system of the pathologist’s lab-
oratory. This decentralized PALGA system automati-
cally collects data from the local computer system and
takes care of communication with the central PALGA
databank. These decentralized systems also perform
checks on data and reports entered by the local pathol-
ogist to ensure the quality and completeness of data
going into the national databank.
When the local pathologist writes his/her pathol-
ogy report, he/she adds to the standard description
of macro/microscopic characteristics, ancillary tech-
niques and conclusion, a series of standardized codes
describing the nature of material analysed, the method
of obtaining the material and the diagnosis. Subse-
quently, the decentralized PALGA system automat-
ically generates a standardized, thesaurus-coded ex-
cerpt of the report containing a limited number of pa-
tient data (encrypted), a report identifier, (part of) the
conclusions, and the so-called PALGA diagnosis, a
coded diagnosis line based upon standard pathology
terminology (Table 1). Excerpts are transferred to the
central databank for retrieval on a daily basis. Patient
identifiers include date of birth, gender and the first
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Table 1
The standardized PALGA diagnosis
Element Description
Thesaurus PALGA thesaurusa
Classification axes T: Topography (localization)
M: Morphology (nature of tissue change)
E: Etiology
F: Function (functional abnormality)
P: Procedure
D: Diseases
Diagnosis line (format) Topography*technique*diagnosis
(e.g., uterus*extirpation*myoma’;
mamma*biopsy*adenocarcinoma)
a Derived from SNOMED (Systematized Nomenclature of Medi-
cine), College of American Pathologists, version 1982.
eight letters of the patient’s family name. These iden-
tifiers as well as those identifying the submitting labo-
ratory are transferred in an encrypted form, thus secur-
ing the privacy of the patient and the laboratory. En-
crypting takes place locally at the laboratory when its
decentralized system contacts the central databank.
2.2. Central databank
Excerpts transferred to the central databank are
checked automatically before they are submitted by the
decentralized system as well as upon receipt by the
central databank. These checks include the diagnostic
terminology used and the structure and completeness
of the diagnosis line. In addition, the corresponding
classification code is added to each diagnostic term ap-
pearing in the excerpt. Each submitted excerpt is regis-
tered in the central databank, even if it contains errors.
In case of errors, the submitting laboratory will receive
an error notification requesting the re-submission of a
corrected version of the excerpt. When a corrected ver-
sion is submitted, the original excerpt in the central
databank is overwritten by the corrected version.
Through the procedures described above, which re-
quire only a minimal effort on the part of the par-
ticipating laboratories, PALGA’s Central Information
System (CIPA) is filled with a continuously increas-
ing amount of information. This information is de-
rived from all histopathological and cytopathological
evaluations conducted in The Netherlands, and supple-
mented by evaluations conducted through the national
screening program for cancer of the uterine cervix, and
all post mortem investigations.
2.3. Communication and information exchange
A dedicated communication and information ex-
change infrastructure constitutes the ‘wiring’ of the
PALGA system. Communication and information ex-
change between authorized parties within this sys-
tem takes place via telephone lines, not web-based,
contributing to the security of data exchange. Par-
ties involved in communication and data exchange
are the participating pathology laboratories and certain
screening organizations in the Netherlands, such as the
organizations conducting the national screening pro-
grams for cancer of the uterine cervix and breast can-
cer.
Other individuals or groups do not get direct access
to the PALGA system. However, if an application for a
search question, submitted by an external party is ap-
proved, the relevant data will be made available to that
party through an authorized intermediate having access
to the PALGA system. Patients’ identity will not be re-
leased to external parties, however.
3. Applications of the PALGA system
With millions of excerpt in its central databank, in-
cluding excerpts of all pathology reports generated in
The Netherlands as of 1991, the PALGA system is a
powerful tool that could potentially serve various pur-
poses, including daily patient care, disease registries,
population-based studies, and epidemiological and sci-
entific research.
3.1. Patient care
One of the core functions of PALGA is to support
patient care on a daily basis. When a local pathologist
is consulted on a specific patient and enters a new eval-
uation, the decentralized computer system automati-
cally checks the central PALGA databank for infor-
mation possibly available on that patient. The pathol-
ogist will then see all previous pathology evaluations
the patient has undergone, their outcome and the iden-
tity of the laboratories that conducted these evaluations
to the extent available in the databank. Thus, PALGA
may contribute to optimal patient care by providing the
patient’s complete pathology history to the consulting
pathologist. Conversely, the availability of an easily ac-
cessible (to participating pathologists) central archive
provides a strong motivation for pathologists to con-
tinue contributing data and to maintain the quality of
data in the PALGA system.
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3.2. Cancer registry and cancer screening
The PALGA databank is a very useful source of in-
formation for disease registries and population-based
health studies in The Netherlands. For instance,
PALGA is an important supplier of data to the Dutch
cancer registry [40]. The cancer registry receives over-
views of all new histologically or cytologically con-
firmed malignant tumours on a weekly basis. In ad-
dition, PALGA plays a central role in the population-
based screening program for cancer of the uterine
cervix [4,12,42]. Results of all PAP smears are record-
ed in the PALGA system in a standardized manner and
invitations for repeat evaluations are generated auto-
matically. Similarly, the Dutch breast cancer screening
program uses the PALGA system to collect follow-up
data from regular healthcare sources on women testing
positive in the screening program. PALGA will also
have an important role in the planned screening pro-
gram for colorectal cancer in the Netherlands [9].
3.3. Research questions form third parties
Numerous scientific papers and many dissertations
have been, and continue to be, published for which
the PALGA databank has provided data. In principle,
anyone with a relevant question may request permis-
sion for the use of data in the PALGA databank. Annu-
ally, forty to sixty applications for permission are be-
ing received, mainly from investigators in The Nether-
lands. Questions may be related to epidemiology, but
may also address pathological diagnosis and follow-
up. Applications must be made in writing and be moti-
vated by the applicant. They are reviewed by PALGA’s
Scientific Advisory Board for validity of the research
question(s) to be addressed and by PALGA’s Privacy
Protection College. If both committees issue a posi-
tive advice, permission may be granted by the Board
of PALGA. Depending on the background of the appli-
cant, more or less detailed data will be made available.
For certain questions, approval by a medical-ethical
review board may be required. A user fee is charged
for services to others than the pathologists contribut-
ing excepts to PALGA. Examples of recent research
questions addressed by means of data from the PALGA
databank can be found in the references [2,3,5,7,8,10,
11,13–27,30,32–39,41,43–45].
4. Structured reporting
Traditionally, pathology reports are relatively well
structured and contain information on the clinical
question, macroscopic characteristics and microscopic
evaluation of the specimen and the concluding diagno-
sis. Yet, pathologists have been relatively free in the
way they present relevant information under each of
these headings, but this is gradually changing. Mul-
tiple initiatives exist to determine the minimally re-
quired datasets to be reported for different types of
pathology specimens [28,31]. Increasingly, such stan-
dards are developed through multidisciplinary initia-
tives. Obviously, for evidence-based patient care stan-
dardized pathology reports are of major importance.
Also for research applications, standardized pathology
reporting holds great promises. In addition to stan-
dards on which items should be reported, standardiza-
tion also concerns data formats in which these items
should be reported, and the databases in which these
data should be stored.
The PALGA databank and its management structure
provide a great opportunity in this respect. For a spe-
cific subset of samples, i.e. cervical cytology speci-
mens, standardized reporting using a defined dataset,
and databanking using fields with coded, searchable
variables, has been operational for many years already.
At present, initiatives are underway to implement this
type of standardization for other types of samples,
including surgical oncology specimens of the large
bowel, breast, lung and other organs. To facilitate the
use of these pro formas in combination with PALGA,
a dedicated software module has been developed that
will appear on top of the client software when the
pathologist reports a specimen of this type. This soft-
ware module will provide standardised entry forms.
This will yield a standardised report for routine patient
care as well as storage of fully searchable data in the
central databank. On a nationwide basis this will allow
specific queries like “all breast cancers smaller than
one centimetre with more than three positive lymph
nodes in a given year”. The current use of excerpts
and diagnosis codes is much more prone to errors in
data entry and coding and does not allow such detailed
queries.
5. Biobanking
Pathology archives contain millions of tissue sam-
ples, either frozen or formaldehyde-fixed and embed-
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ded in paraffin blocks. A subset of these samples has
specifically been collected for research purposes with
informed consent of the patients involved. For the
larger part, this is material left over from completed di-
agnostic procedures. Such material may later on prove
clinically relevant for the patient and/or his/her rel-
atives. In addition, this material provides a tremen-
dously powerful and important resource for scientific
research as it allows correlations to be made between
phenotypic features and biological characteristics of
disease. The latter can be obtained by analysing tis-
sue samples with state-of-the-art molecular technolo-
gies. In the Netherlands, the adequate secondary use of
left-over tissue samples for scientific research is reg-
ulated by of a self-regulatory code of conduct, devel-
oped by the Federation of Dutch Medical Scientific So-
cieties [6].
The PALGA databank has a dual role in this type
of research. Firstly, PALGA serves as the index of the
tissue archive, either within the local institution or na-
tionwide. Secondly, the pathology reports in the data-
bank provide a major source of information on disease
phenotype in all cases. Obviously, the implementation
of structured reports in the PALGA databank will ben-
efit both functions. The great potential of the PALGA
system in this respect is underscored by a recent re-
port of the Netherlands Academy of Sciences. Recom-
mendations are made to involve PALGA in projects for
improving the research infrastructure for translational
biomedical research in The Netherlands [29].
6. Concluding remarks
The PALGA system is a unique, highly automated
pathology archiving and communication tool that pro-
vides considerable support to pathologists in their daily
practices. The technology and procedures of PALGA
were designed from the beginning to minimize the
amount of effort required by the participating labo-
ratories. This approach has resulted in the joining of
the PALGA network by all 64 histopathology and cy-
topathology laboratories in The Netherlands and a con-
tinuously expanding automated archive of excerpts of
pathology reports with currently about 42 million ex-
cepts on nearly 10 million patients in the central data-
bank.
The PALGA system not only supports pathologists
in daily practice by giving them easy access to current
and historical data on their patients, it also supports the
Dutch cancer registration, national screening organi-
zations, and investigators wishing to address research
questions in various domains, including epidemiology,
pathology, and molecular biology of disease.
Acknowledgements
We are indebted to the many pathologists, scientists
and other collaborators who have contributed to devel-
oping and maintaining PALGA.
References
[1] F. Bijlsma and E.P. van der Esch, [PALGA, of labor pains of the
Pathological Anatomical District Automatized Archives], Ned.
Tijdschr. Geneeskd. 116 (1972), 902–903.
[2] A.A. Botterweck, P.A. van den Brandt and R.A. Goldbohm,
A prospective cohort study on vegetable and fruit consumption
and stomach cancer risk in The Netherlands, Am. J. Epidemiol.
148 (1998), 842–853.
[3] S. Bulk, F.J. van Kemenade, L. Rozendaal et al., The Dutch
CISOE-A framework for cytology reporting increases efficacy
of screening upon standardisation since 1996, J. Clin. Pathol.
57 (2004), 388–393.
[4] S. Bulk, F.J. van Kemenade, L. Rozendaal and C.J. Meijer, The
Dutch CISOE-A framework for cytology reporting increases
efficacy of screening upon standardisation since 1996, J. Clin.
Pathol. 57 (2004), 388–393.
[5] A.M. Cleton-Jansen, M.C. Timmerman, M.J. van de Vijver
et al., A distinct phenotype characterizes tumors from a puta-
tive genetic trait involving chondrosarcoma and breast cancer
occurring in the same patient, Lab. Invest. 84 (2004), 191–202.
[6] Code for adequate secondary use of data (2004), Code for ad-
equate secondary use of tissue (2001), http://www.federa.org/
[accessed 31 December 2006].
[7] C.G. Csizmadia, M.L. Mearin, B.M. von Blomberg et al., An
iceberg of childhood coeliac disease in the Netherlands, Lancet
353 (1999), 813–814.
[8] E. de Bree, F.A. Zoetmulder, R.B. Keus et al., Incidence and
treatment of recurrent plantar fibromatosis by surgery and post-
operative radiotherapy, Am. J. Surg. 187 (2004), 33–38.
[9] M. de Visser, M. van Ballegooijen, S.M. Bloemers et al., Report
on the Dutch consensus development meeting for implementa-
tion and further development of population screening for col-
orectal cancer based on FOBT, Cell. Oncol. 27 (2005), 17–29.
[10] W.L. Diemont, O.J. ten Thije and C.H. ten Napel, Unsuspected
herpes esophagitis: properties of eight non-HIV-related cases,
Neth. J. Med. 37 (1990), A54–A55.
[11] M.J. Dirx, P.A. van den Brandt, R.A. Goldbohm et al., Energy
restriction in childhood and adolescence and risk of prostate
cancer: results from the Netherlands Cohort Study, Am. J. Epi-
demiol. 154 (2001), 530–537.
[12] M. Geertsen, A.G. Bais, H. Beerman and T.J. Helmerhorst, Fol-
low up after an abnormal pap smear: time interval acceptable,
nature of follow up leaves room for improvement, Ned. Tijd-
schr. Geneeskd. 147 (2003) 2430–2434 [Article in Dutch].
24 M. Casparie et al. / Pathology databanking and biobanking in The Netherlands
[13] E.K. George, M.L. Mearin, H.C. Franken et al., Twenty years
of childhood coeliac disease in The Netherlands: a rapidly in-
creasing incidence?, Gut 40 (1997), 61–66.
[14] R.W. Giard and J. Hermans, Use and accuracy of fine-needle
aspiration cytology in histologically proven thyroid carcinoma:
an audit using a national nathology database, Cancer 90
(2000), 330–334.
[15] W.G. Goettsch, S.D. Bos, N. Breekveldt-Postma et al., Inci-
dence of gastrointestinal stromal tumours is underestimated:
results of a nation-wide study, Eur. J. Cancer 41 (2005), 2868–
2872.
[16] A. Hanselaar, M. van Loosbroek, O. Schuurbiers et al., Clear
cell adenocarcinoma of the vagina and cervix. An update of the
central Netherlands registry showing twin age incidence peaks,
Cancer 79 (1997), 2229–2236.
[17] E.I. Hauben, J. Arends, J.P. Vandenbroucke et al., Multiple
primary malignancies in osteosarcoma patients. Incidence and
predictive value of osteosarcoma subtype for cancer syndromes
related with osteosarcoma, Eur. J. Hum. Genet. 11 (2003),
611–618.
[18] E.I. Hauben, G. Jundt, A.M. Cleton-Jansen et al., Desmoplas-
tic fibroma of bone: an immunohistochemical study includ-
ing β-catenin expression and mutational analysis for β-catenin,
Human Pathology 36 (2005), 1025–1030.
[19] M.P.W.A. Houben, J.W.W. Coebergh, R.M.C. Herings et al.,
The association between antihypertensive drugs and glioma,
Br. J. Cancer (2006), 752–756.
[20] F. Loeve, M. van Ballegooijen, R. Boer et al., Colorectal cancer
risk in adenoma patients: a nation-wide study, Int. J. Cancer
111 (2004), 147–151.
[21] E.M. Mathus-Vliegen, H. van Halteren and G.N. Tytgat, Malig-
nant lymphoma in coeliac disease: various manifestations with
distinct symptomatology and prognosis?, J. Intern. Med. 236
(1994), 43–49.
[22] A.E. Odink, C.J. van Asperen, J.P. Vandenbroucke et al., An
association between cartilaginous tumours and breast cancer in
the national pathology registration in The Netherlands points
towards a possible genetic trait, J. Pathol. 193 (2001), 190–192.
[23] S.J. Otto, I. van der Cruijsen, M.K. Liem et al., Effective PSA
contamination in the Rotterdam section of the European Ran-
domized Study of Screening for Prostate Cancer, Int. J. Cancer
105 (2003), 394–399.
[24] P.N. Post, E.J. Kuipers and C.J. Meijer, Declining incidence of
peptic ulcer but not of its complications: a nation-wide study in
The Netherlands, Aliment. Pharmacol. Ther. 1 (2006), 1587–
1593.
[25] F.H. Rampen, J.I. Casparie-van Velsen, B.E. van Huystee et al.,
False-negative findings in skin cancer and melanoma screen-
ing, J. Am. Acad. Dermatol. 33 (1995), 59–63.
[26] J.M. Rhodes, Cholesterol crystal embolism: an important
“new” diagnosis for the general physician, Lancet 347 (1996),
1641.
[27] R.M. Roumen, Anorectal melanoma in The Netherlands: a re-
port of 63 patients, Eur. J. Surg. Oncol. 22 (1996), 598–601.
[28] Royal College of Pathologists, General introduction, Datasets
for histopathology reporting on cancers, http://www.rcpath.
org/index.asp [accessed 31 December 2006].
[29] Royal Netherlands Academy of Arts and Sciences, Foresight
Committee on Multifactorial Diseases in the Genom cs Era
(2006), http://www.knaw.nl/publicaties/pdf/20041002.pdf.
[30] L.J. Schouten, R.A. Goldbohm and P.A. van den Brandt, An-
thropometry, physical activity, and endometrial cancer risk: re-
sults from the Netherlands Cohort Study, J. Natl. Cancer Inst.
96 (2004), 1635–1638.
[31] Templates for pathology reporting of common malignancies,
http://www.pathology.nl/ [accessed 31 December 2006].
[32] T. van Dalen, H.J. Hoekstra, A.N. van Geel et al., Locore-
gional recurrence of retroperitoneal soft tissue sarcoma: sec-
ond chance of cure for selected patients, Eur. J. Surg. Oncol. 27
(2001), 564–568.
[33] M.E. van den Akker-van Marle, M. van Ballegooijen, G.J.
van ortmarssen et al., Cost-effectiveness of cervical cancer
screening: comparison of screening policies, J. Natl. Cancer
Inst. 94 (2002), 193–204.
[34] M.J. van der, J.L. Blaauwgeers, T.G. Sutedja et al., Granular
cell tumors of the tracheobronchial tree, J. Thorac. Cardiovasc.
Surg. 126 (2003), 740–743.
[35] B.A. van Dijk, L.J. Schouten, C.A. Hulsbergen-van de Kaa
et al., Risk factors, genetic predisposition and mutations in the
VHL gene in sporadic renal cell carcinoma: The Netherlands
Cohort Study, IARC Sci. Publ. 156 (2002), 509–510.
[36] M.C. van Dijk, P.D. Rombout, W.J. Mooi et al., Allelic imbal-
ance in the diagnosis of benign, atypical and malignant Spitz
tumours, J. Pathol. 197 (2002), 170–178.
[37] J.J. van Lanschot, J.B. Hulscher, C.J. Buskens et al., Hospital
volume and hospital mortality for esophagectomy, Cancer 91
(2001), 1574–1578.
[38] F.E. van Leeuwen, J. Benraadt, J.W. Coebergh et al., Risk of
endometrial cancer after tamoxifen treatment of breast cancer,
Lancet 343 (1994), 448–452.
[39] K.C. Veenhuizen, P.E. de Wit, W.J. Mooi et al., Quality assess-
ment by expert opinion in melanoma pathology: experience of
the pathology panel of the Dutch Melanoma Working Party,
J. Pathol. 182 (1997), 266–272.
[40] Vereniging van Integrale Kankercentra (VIKC) / Association
of Comprehensive Cancer Centres, Incidence of cancer in the
Netherlands 1999/2000, Eleventh report of the Netherlands
Cancer Registry, 2003.
[41] G.P. Vooijs, I.A. Casparie-van Velsen, F.A. Peters et al., Na-
tional registry of cervical cytologic diagnoses in The Nether-
lands, Acta Cytol. 33 (1989), 825–830.
[42] G.P. Vooijs, I.A. Casparie-van Velsen, F.A. Peters and
H.L. Beck, National registry of cervical cytologic diagnoses in
The Netherlands, Acta Cytol. 33 (1989), 825–830.
[43] W. Willemsen, R. Kruitwagen, B. Bastiaans et al., Ovarian
stimulation and granulosa-cell tumour, Lancet 341 (1993),
986–988.
[44] P.C. Witt Hamer, M.J. Verstegen, R.J. de Haan et al., High risk
of acute deterioration in patients harboring symptomatic col-
loid cysts of the third ventricle, J. Neurosurg. 96 (2002), 1041–
1045.
[45] L.H. Zaal, W.J. Mooi, H. Klip et al., Risk of malignant transfor-
mation of congenital melanocytic nevi: a retrospective nation-
wide study from The Netherlands, Plast. Reconstr. Surg. 116
(2005), 1902–1909.
